TORII PHARMACEUTICAL CO., LTD. (E00934) Stock Price

Torii Pharmaceutical is primarily engaged in the manufacturing and sale of pharmaceutical products. The company operates through four main business segments: kidney and dialysis, dermatological diseases, allergen immunotherapy, and other areas. Products offered in each segment are developed to address specific medical needs.

In the kidney and dialysis segment, the company provides Riona Tablets and Remitch. Riona Tablets are used to treat hyperphosphatemia and iron deficiency anemia, while Remitch is an oral antipruritic agent. These products contribute to the treatment of kidney disease and dialysis patients.

In the dermatological diseases segment, the company offers Colechtim Ointment, Antebate, and Locoid. Colechtim Ointment is a topical Janus kinase (JAK) inhibitor, while Antebate and Locoid are topical corticosteroids. These products are used in the treatment of skin diseases.

In the allergen immunotherapy segment, the company provides Cedacuran Cedar Pollen Sublingual Tablets and Miticuran Dust Mite Sublingual Tablets. Cedacuran is an allergen immunotherapy treatment for cedar pollen allergy, while Miticuran is used to treat dust mite allergies. These products help alleviate allergy symptoms.

In other areas, the company offers Biothree and Oradeo Capsules. Biothree is a live bacterial preparation (intestinal flora regulator), and Oradeo Capsules are plasma kallikrein inhibitors. These products support digestive health and treat specific blood disorders.

Additionally, JT, the parent company of Torii Pharmaceutical, oversees a cash management system for domestic group companies. Torii Pharmaceutical participates in this system through fund deposits as a means of settlement, thereby improving capital management efficiency.

Torii Pharmaceutical is pursuing long-term growth based on its corporate philosophy "Torii Pharmaceutical's Mission." The company prioritizes trust with patients and healthcare professionals, with a commitment to contributing to healthcare. To achieve this, the company values "TORII's POLICY," developed by its employees, and adopts the 4S model as its fundamental management principle.

Under its medium- to long-term business vision "VISION2030," the company aims to become a pharmaceutical manufacturer that deeply understands medical needs and provides valuable new drugs. By 2030, the company targets sales exceeding 8 billion yen and record-high operating profit, while pursuing aggressive business investments. This approach ensures sustainable growth and enhances corporate value.

The 2024-2026 medium-term management plan positions new drug development and market introduction activities as growth strategies. Specifically, the company is advancing development of Vitamark Cream, TO-208, and TO-210 to maximize product value. To maintain stakeholder trust, the company is strengthening stable supply systems and enhancing corporate governance.

Furthermore, the 2025-2027 medium-term management plan prioritizes the market expansion of growth-stage new drugs and acquisition of new products. Through these initiatives, the company is promoting corporate culture reform and work style reform to achieve sustainable growth. Regarding shareholder returns, the company maintains stable dividends as its basic policy while working to enhance corporate value.